Merck & Co. Inc. (MRK)

$ 129.48
   
  • Change Today:
    $0.11
  • 52 Week High: $131.95
  • 52 Week Low: $100.18
  • Currency: US Dollars
  • Shares Issued: 2,531.63m
  • Volume: 7,338,462
  • Market Cap: $327,796m
  • RiskGrade: 92

AstraZeneca's Lynparza cancer drug approved by Japan

By Frank Prenesti

Date: Tuesday 29 Dec 2020

LONDON (ShareCast) - (Sharecast News) - AstraZeneca and Merck's Lynparza has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers, the UK-based pharmaceutical company said on Tuesday.
The concurrent approvals by the Japanese Ministry of Health, Labour, and Welfare are based on positive results from the PAOLA-1, PROfound and POLO Phase III trials, which each were published in The New England Journal of Medicine.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Merck Market Data

Currency US Dollars
Share Price $ 129.48
Change Today $ 0.11
% Change 0.09 %
52 Week High $131.95
52 Week Low $100.18
Volume 7,338,462
Shares Issued 2,531.63m
Market Cap $327,796m
RiskGrade 92

What The Brokers Say

Strong Buy 11
Buy 12
Neutral 3
Sell 0
Strong Sell 0
Total 26
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 14-Jun-2024

Time Volume / Share Price
16:00 1,212,507 @ $129.48
15:59 200 @ $129.48
15:59 500 @ $129.48
15:59 200 @ $129.48
15:59 100 @ $129.50

Top of Page